Genelabs sales and marketing update

GNLB posted product sales of $2.7 million in the third quarter ended Sept. 30 compared to $400,000 in the third quarter last year. GNLB attributed the rise to increased sales by Singapore-based Diagnostic Biotechnology Ltd., which the company acquired in March.

The net loss was $4.4 million (20 cents per share) on revenues of $4.4 million vs. a loss of $4.4 million (25 cents) on revenues of $1 million in the quarter last year. ...